1 citations
,
September 2022 in “Nepal journal of dermatology, venereology & leprology” Apremilast shows promise for several skin conditions but needs more research.
18 citations
,
August 2024 in “eLife” JAK inhibition may help manage autoimmune conditions in Down syndrome.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
May 2025 in “Pakistan Armed Forces Medical Journal” Dithranol is more effective than Tacrolimus for hair regrowth in alopecia areata.
Higher TGF-β signaling may increase skin cancer risk in organ transplant recipients.
253 citations
,
April 2014 in “Drugs” Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
November 2025 in “The Journal of Immunology” A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.
22 citations
,
August 2011 in “Journal of the American Academy of Dermatology” Topical tacrolimus can effectively treat erosive pustular dermatosis and related hair loss.
Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
September 2010 in “Institutional Repositories DataBase (IRDB)” Sorafenib can cause a temporary skin condition that goes away after stopping the drug.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
3 citations
,
November 2021 in “Frontiers in medicine” Methotrexate effectively controls eye inflammation in Japanese patients with non-infectious uveitis but requires careful monitoring for side effects.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
September 2023 in “Journal of the American Academy of Dermatology” 2 citations
,
December 2024 in “Journal of Dermatological Treatment”
June 2016 in “Annals of the rheumatic diseases” Methotrexate is effective for treating rheumatoid arthritis but requires regular monitoring.
5 citations
,
January 2016 in “Elsevier eBooks” Using a specific binding agent and low doses of FK506 can stimulate stem cells, speeding up skin healing by 25% and improving skin quality in rats and mice.
November 2021 in “International journal of life science and pharma research” The new gel for psoriasis is effective, stable, and easy to apply.
BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.
30 citations
,
June 2017 in “Journal of cutaneous medicine and surgery” Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.
70 citations
,
February 2018 in “Seminars in Arthritis and Rheumatism” Belimumab reduces disease activity, steroid use, and flares in lupus patients.
3 citations
,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
63 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
June 2025 in “Theranostics” Rapamycin-primed exosomes can significantly boost hair regrowth.
March 2018 in “Dermatologic Surgery”